Organisation paid for research Program year 2025 Source: CMS Open Payments

Windsor Dermatology

Neither a doctor nor a teaching hospital

Research payments

$1,288,303

467 payments

Through program year 2025, Windsor Dermatology is reported as receiving $1,288,303 in research payments, across 467 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$97,045	150
2024	Research	$164,214	213
2023	Research	$440,707	3
2022	Research	$7,915	2
2021	Research	$195,171	47
2020	Research	$304,552	50
2019	Research	$78,699	2

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $542,894 7 payments
AbbVie, Inc. $499,494 96 payments
Incyte Corporation $236,003 361 payments
Celgene Corporation $8,063 1 payment
Novartis Pharmaceuticals Corporation $1,620 1 payment
Amgen Inc. $229 1 payment

Studies the money was for Research payments · program years 2019–2025

A Single Center Study to Evaluate the Effectiveness and Safety of Deucravacitinib in combination with Enstilar for Moderate to Severe Plaque Psoriasis $288,402 1 payment
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) $183,856 5 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $129,899 183 payments
M15-997 $105,209 17 payments
M16-813 $71,731 9 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $70,636 1 payment
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $66,736 15 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $66,326 79 payments
M16-047 $51,320 11 payments
P10-023 $35,260 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.